Marta Filipa Freire Vaz Batista, Inês Eiriz, Amanda Fitzpatrick, Fanny Le Du, Sofia Braga, Diogo Alpuim Costa
{"title":"Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis.","authors":"Marta Filipa Freire Vaz Batista, Inês Eiriz, Amanda Fitzpatrick, Fanny Le Du, Sofia Braga, Diogo Alpuim Costa","doi":"10.1159/000526431","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, recent studies of novel HER2-targeted agents have focused on HER2+ BM patients, addressing stable but also progressing BM and leptomeningeal carcinomatosis (LMC).</p><p><strong>Summary: </strong>This review aimed to summarize the most relevant data on treating patients with HER2+ BM and LMC.</p><p><strong>Key messages: </strong>The treatment paradigm for patients with HER2+ MBC has changed. Local therapies play an important role, but accumulating evidence on the intracranial activity and clinical benefit of anti-HER2 targeting therapies might lead to a shift in the paradigm on treating BM in the next few years towards more widespread use of systemic therapy.</p>","PeriodicalId":72460,"journal":{"name":"","volume":"17 6","pages":"524-532"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801402/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000526431","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, recent studies of novel HER2-targeted agents have focused on HER2+ BM patients, addressing stable but also progressing BM and leptomeningeal carcinomatosis (LMC).
Summary: This review aimed to summarize the most relevant data on treating patients with HER2+ BM and LMC.
Key messages: The treatment paradigm for patients with HER2+ MBC has changed. Local therapies play an important role, but accumulating evidence on the intracranial activity and clinical benefit of anti-HER2 targeting therapies might lead to a shift in the paradigm on treating BM in the next few years towards more widespread use of systemic therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
